INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis
NASDAQ:IART - Nasdaq - US4579852082 - Common Stock - Currency: USD
IART gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. IART has a medium profitability rating, but doesn't score so well on its financial health evaluation. IART has a bad growth rate and is valued cheaply.
1. Profitability
1.1 Basic Checks
In the past year IART was profitable.
IART had a positive operating cash flow in the past year.
IART had positive earnings in each of the past 5 years.
In the past 5 years IART always reported a positive cash flow from operatings.
1.2 Ratios
IART's Return On Assets of -0.16% is fine compared to the rest of the industry. IART outperforms 69.47% of its industry peers.
The Return On Equity of IART (-0.43%) is better than 70.53% of its industry peers.
The Return On Invested Capital of IART (4.93%) is better than 77.89% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IART is in line with the industry average of 8.09%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.16% | ||
| ROE | -0.43% | ||
| ROIC | 4.93% |
ROA(3y)3.63%
ROA(5y)3.23%
ROE(3y)8.1%
ROE(5y)7.34%
ROIC(3y)6.75%
ROIC(5y)6.66%
1.3 Margins
IART's Profit Margin has been stable in the last couple of years.
IART has a better Operating Margin (11.84%) than 80.53% of its industry peers.
In the last couple of years the Operating Margin of IART has grown nicely.
IART has a Gross Margin (59.29%) which is comparable to the rest of the industry.
IART's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.84% | ||
| PM (TTM) | N/A | ||
| GM | 59.29% |
OM growth 3Y3.4%
OM growth 5Y2.16%
PM growth 3Y-23.36%
PM growth 5Y1.25%
GM growth 3Y-0.76%
GM growth 5Y-0.14%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so IART is destroying value.
The number of shares outstanding for IART has been reduced compared to 1 year ago.
The number of shares outstanding for IART has been reduced compared to 5 years ago.
IART has a worse debt/assets ratio than last year.
2.2 Solvency
IART has an Altman-Z score of 1.38. This is a bad value and indicates that IART is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of IART (1.38) is comparable to the rest of the industry.
IART has a debt to FCF ratio of 47.52. This is a negative value and a sign of low solvency as IART would need 47.52 years to pay back of all of its debts.
IART's Debt to FCF ratio of 47.52 is fine compared to the rest of the industry. IART outperforms 67.37% of its industry peers.
A Debt/Equity ratio of 0.79 indicates that IART is somewhat dependend on debt financing.
IART's Debt to Equity ratio of 0.79 is on the low side compared to the rest of the industry. IART is outperformed by 73.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 47.52 | ||
| Altman-Z | 1.38 |
ROIC/WACC0.64
WACC7.66%
2.3 Liquidity
A Current Ratio of 1.20 indicates that IART should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.20, IART is doing worse than 84.21% of the companies in the same industry.
A Quick Ratio of 0.73 indicates that IART may have some problems paying its short term obligations.
With a Quick ratio value of 0.73, IART is not doing good in the industry: 89.47% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.2 | ||
| Quick Ratio | 0.73 |
3. Growth
3.1 Past
IART shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.27%.
The Earnings Per Share has been growing slightly by 5.08% on average over the past years.
The Revenue has been growing slightly by 1.45% in the past year.
Measured over the past years, IART shows a small growth in Revenue. The Revenue has been growing by 0.92% on average per year.
EPS 1Y (TTM)-21.27%
EPS 3Y8.16%
EPS 5Y5.08%
EPS Q2Q%-46.05%
Revenue 1Y (TTM)1.45%
Revenue growth 3Y3.96%
Revenue growth 5Y0.92%
Sales Q2Q%-0.93%
3.2 Future
Based on estimates for the next years, IART will show a small growth in Earnings Per Share. The EPS will grow by 2.69% on average per year.
IART is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.90% yearly.
EPS Next Y-19.35%
EPS Next 2Y-9.05%
EPS Next 3Y-2.93%
EPS Next 5Y2.69%
Revenue Next Year4.44%
Revenue Next 2Y5.32%
Revenue Next 3Y5%
Revenue Next 5Y5.9%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
IART is valuated reasonably with a Price/Earnings ratio of 10.50.
97.89% of the companies in the same industry are more expensive than IART, based on the Price/Earnings ratio.
IART is valuated cheaply when we compare the Price/Earnings ratio to 28.58, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 10.16, the valuation of IART can be described as very reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IART indicates a rather cheap valuation: IART is cheaper than 96.84% of the companies listed in the same industry.
IART's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.47.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.5 | ||
| Fwd PE | 10.16 |
4.2 Price Multiples
93.68% of the companies in the same industry are more expensive than IART, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, IART is valued a bit cheaper than the industry average as 75.79% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 52.88 | ||
| EV/EBITDA | 10.88 |
4.3 Compensation for Growth
The decent profitability rating of IART may justify a higher PE ratio.
A cheap valuation may be justified as IART's earnings are expected to decrease with -2.93% in the coming years.
PEG (NY)N/A
PEG (5Y)2.07
EPS Next 2Y-9.05%
EPS Next 3Y-2.93%
5. Dividend
5.1 Amount
No dividends for IART!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INTEGRA LIFESCIENCES HOLDING
NASDAQ:IART (1/24/2025, 8:00:02 PM)
After market: 26.05 0 (0%)26.05
+0.45 (+1.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.17%
Inst Owner Change-0.07%
Ins Owners3.12%
Ins Owner Change-0.03%
Market Cap2.01B
Analysts52.22
Price Target26.52 (1.8%)
Short Float %4.34%
Short Ratio4.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.22%
Min EPS beat(2)-0.79%
Max EPS beat(2)3.22%
EPS beat(4)1
Avg EPS beat(4)-0.8%
Min EPS beat(4)-3.39%
Max EPS beat(4)3.22%
EPS beat(8)3
Avg EPS beat(8)1.92%
EPS beat(12)5
Avg EPS beat(12)3.13%
EPS beat(16)9
Avg EPS beat(16)6.5%
Revenue beat(2)0
Avg Revenue beat(2)-0.71%
Min Revenue beat(2)-0.77%
Max Revenue beat(2)-0.64%
Revenue beat(4)0
Avg Revenue beat(4)-1.01%
Min Revenue beat(4)-2.52%
Max Revenue beat(4)-0.09%
Revenue beat(8)1
Avg Revenue beat(8)-1.08%
Revenue beat(12)2
Avg Revenue beat(12)-0.8%
Revenue beat(16)4
Avg Revenue beat(16)-0.65%
PT rev (1m)-7.51%
PT rev (3m)-3.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.78%
EPS NY rev (1m)0%
EPS NY rev (3m)0.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.5 | ||
| Fwd PE | 10.16 | ||
| P/S | 1.28 | ||
| P/FCF | 52.88 | ||
| P/OCF | 14.63 | ||
| P/B | 1.32 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.88 |
EPS(TTM)2.48
EY9.52%
EPS(NY)2.56
Fwd EY9.84%
FCF(TTM)0.49
FCFY1.89%
OCF(TTM)1.78
OCFY6.84%
SpS20.28
BVpS19.72
TBVpS-10.43
PEG (NY)N/A
PEG (5Y)2.07
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.16% | ||
| ROE | -0.43% | ||
| ROCE | 5.87% | ||
| ROIC | 4.93% | ||
| ROICexc | 5.41% | ||
| ROICexgc | 28.31% | ||
| OM | 11.84% | ||
| PM (TTM) | N/A | ||
| GM | 59.29% | ||
| FCFM | 2.43% |
ROA(3y)3.63%
ROA(5y)3.23%
ROE(3y)8.1%
ROE(5y)7.34%
ROIC(3y)6.75%
ROIC(5y)6.66%
ROICexc(3y)7.7%
ROICexc(5y)7.53%
ROICexgc(3y)26.08%
ROICexgc(5y)25.66%
ROCE(3y)8.04%
ROCE(5y)7.93%
ROICexcg growth 3Y-0.69%
ROICexcg growth 5Y-4.78%
ROICexc growth 3Y2.49%
ROICexc growth 5Y-0.08%
OM growth 3Y3.4%
OM growth 5Y2.16%
PM growth 3Y-23.36%
PM growth 5Y1.25%
GM growth 3Y-0.76%
GM growth 5Y-0.14%
F-Score4
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 47.52 | ||
| Debt/EBITDA | 3.77 | ||
| Cap/Depr | 73.99% | ||
| Cap/Sales | 6.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 42.99% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.2 | ||
| Quick Ratio | 0.73 | ||
| Altman-Z | 1.38 |
F-Score4
WACC7.66%
ROIC/WACC0.64
Cap/Depr(3y)44.7%
Cap/Depr(5y)62.4%
Cap/Sales(3y)3.49%
Cap/Sales(5y)4.8%
Profit Quality(3y)128.19%
Profit Quality(5y)136.42%
High Growth Momentum
Growth
EPS 1Y (TTM)-21.27%
EPS 3Y8.16%
EPS 5Y5.08%
EPS Q2Q%-46.05%
EPS Next Y-19.35%
EPS Next 2Y-9.05%
EPS Next 3Y-2.93%
EPS Next 5Y2.69%
Revenue 1Y (TTM)1.45%
Revenue growth 3Y3.96%
Revenue growth 5Y0.92%
Sales Q2Q%-0.93%
Revenue Next Year4.44%
Revenue Next 2Y5.32%
Revenue Next 3Y5%
Revenue Next 5Y5.9%
EBIT growth 1Y-34.31%
EBIT growth 3Y7.5%
EBIT growth 5Y3.1%
EBIT Next Year0.21%
EBIT Next 3Y4.32%
EBIT Next 5YN/A
FCF growth 1Y-79.8%
FCF growth 3Y-19.46%
FCF growth 5Y-9.74%
OCF growth 1Y-44.66%
OCF growth 3Y-11.77%
OCF growth 5Y-6.86%